Icahn, ImClone, Bristol-Myers... A 3-Way Marriage (IMCL, BMY)

Health and Healthcare

Published: July 31, 2008 6:59 am

Another biotech giant is biting the dust via a buyout offer. ImClone Systems Inc. (NASDAQ: IMCL) has been given a buyout offer from Bristol-Myers (NYSE: BMY) at $60.00 per share.

As per the filing:

James M. Cornelius, Chairman and Chief Executive Officer of BMS, called Carl C. Icahn, Chairman of the Board of ImClone, to convey an offer by BMS to enter into an agreement to acquire ImClone for $60 per share in cash (the “BMS Offer”). The BMS Offer represents a premium of approximately 30% over the closing price of ImClone common stock on July 30, 2008, a premium of approximately 40% over the one-month average closing price of ImClone common stock, and a premium in excess of 40% over the three-month and one-year average closing prices of ImClone common stock. The BMS Offer was authorized by the BMS Board of Directors.

Yep, another biotech looks to be disappearing.

Jon C. Ogg
July 31, 2008

Take This Retirement Quiz To Get Matched With An Advisor Now ^(Sponsored)

Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.

Click here now to get started.